These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment. Dupont C; Jumas-Bilak E; Doisy C; Aujoulat F; Chiron R; Marchandin H Appl Environ Microbiol; 2018 Dec; 84(23):. PubMed ID: 30217850 [No Abstract] [Full Text] [Related]
11. Severe Achromobacter xylosoxidans infection and loss of sputum bacterial diversity in an adult patient with cystic fibrosis. Talbot NP; Flight WG Paediatr Respir Rev; 2016 Aug; 20 Suppl():27-9. PubMed ID: 27374622 [TBL] [Abstract][Full Text] [Related]
12. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. Waters V; Atenafu EG; Salazar JG; Lu A; Yau Y; Matukas L; Tullis E; Ratjen F J Cyst Fibros; 2012 Jan; 11(1):8-13. PubMed ID: 21849265 [TBL] [Abstract][Full Text] [Related]
13. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. Ridderberg W; Bendstrup KE; Olesen HV; Jensen-Fangel S; Nørskov-Lauritsen N J Cyst Fibros; 2011 Dec; 10(6):466-9. PubMed ID: 21835703 [TBL] [Abstract][Full Text] [Related]
14. Progressive flow-to-volume dysanapsis in cystic fibrosis: a predictor for lung transplantation? Vilozni D; Lavie M; Sarouk I; Efrati O Am J Respir Crit Care Med; 2012 Jul; 186(1):82-7. PubMed ID: 22538801 [TBL] [Abstract][Full Text] [Related]
15. Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study. Edwards BD; Greysson-Wong J; Somayaji R; Waddell B; Whelan FJ; Storey DG; Rabin HR; Surette MG; Parkins MD J Clin Microbiol; 2017 Jul; 55(7):2074-2085. PubMed ID: 28446570 [No Abstract] [Full Text] [Related]
16. Epidemic Achromobacter xylosoxidans strain among Belgian cystic fibrosis patients and review of literature. Cools P; Ho E; Vranckx K; Schelstraete P; Wurth B; Franckx H; Ieven G; Van Simaey L; Van Daele S; Verhulst S; De Baets F; Vaneechoutte M BMC Microbiol; 2016 Jun; 16(1):122. PubMed ID: 27342812 [TBL] [Abstract][Full Text] [Related]
17. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report. Hoyle N; Zhvaniya P; Balarjishvili N; Bolkvadze D; Nadareishvili L; Nizharadze D; Wittmann J; Rohde C; Kutateladze M Res Microbiol; 2018 Nov; 169(9):540-542. PubMed ID: 29777836 [TBL] [Abstract][Full Text] [Related]
18. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. Dalbøge CS; Hansen CR; Pressler T; Høiby N; Johansen HK J Cyst Fibros; 2011 Sep; 10(5):318-25. PubMed ID: 21463972 [TBL] [Abstract][Full Text] [Related]
19. Prevalence and impact on FEV(1) decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis. A single-center, case control study of 165 patients. Vanderhelst E; De Meirleir L; Verbanck S; Piérard D; Vincken W; Malfroot A J Cyst Fibros; 2012 Jan; 11(1):2-7. PubMed ID: 21907637 [TBL] [Abstract][Full Text] [Related]